Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease (HART)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier:
NCT00724048
First received: July 24, 2008
Last updated: July 20, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2011
  Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: February 19, 2013